title: Basiliximab can be administered safely and effectively in a single dose on day 1 postrenal transplantation in patients receiving triple therapy with azathioprine.
authors.affiliation: Department of Nephrology, Institute for Clinical and Experimental Medicine, Prague, Czech Republic.
authors.forename: I
authors.initials: I
authors.lastname: Matl
authors.forename: P
authors.initials: P
authors.lastname: Bachleda
authors.forename: R
authors.initials: R
authors.lastname: Michalsky
authors.forename: P
authors.initials: P
authors.lastname: Navratil
authors.forename: M
authors.initials: M
authors.lastname: Lao
authors.forename: V
authors.initials: V
authors.lastname: Treska
authors.forename: H
authors.initials: H
authors.lastname: Prestele
authors.forename: M
authors.initials: M
authors.lastname: Matthisson
authors.forename: A
authors.initials: A
authors.lastname: Korn
mesh_terms: D000911:Antibodies, Monoclonal / Q000627:therapeutic use*; D001379:Azathioprine / Q000627:therapeutic use*; D000077552:Basiliximab; D001938:Brazil; D004359:Drug Therapy, Combination; D005260:Female; D006084:Graft Rejection / Q000453:epidemiology / Q000473:pathology / Q000517:prevention & control; D006650:Histocompatibility Testing; D006801:Humans; D007165:Immunosuppression Therapy / Q000592:standards; D007239:Infections / Q000453:epidemiology; D016030:Kidney Transplantation / Q000276:immunology* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D011183:Postoperative Complications / Q000453:epidemiology; D011993:Recombinant Fusion Proteins; D012449:Safety; D013997:Time Factors
chemical_list: D000911:Antibodies, Monoclonal; D011993:Recombinant Fusion Proteins; D000077552:Basiliximab; D001379:Azathioprine